NBIX · Neurocrine Biosciences Inc · Executive Compensation
$156.22
-0.35 (-0.22%)
At close · Sep 11
Market Cap
$15.88B
Shares
101.65M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Kyle W. Gano | Chief Executive Officer | $13,448,935 |
| Sanjay Keswani | Chief Medical Officer | $9,007,803 |
| Jude Onyia | Chief Scientific Officer | $7,410,769 |
| Matthew C. Abernethy | Chief Financial Officer | $6,311,912 |
| Strategic Advisor | — | $6,073,032 |
| Eric Benevich | Chief Commercial Officer | $5,888,947 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Kevin Gorman | CEO | $16,018,637 |
| Kevin C. Gorman | Former Chief Executive Officer | $16,018,637 |
| Kyle W. Gano | Chief Executive Officer | $8,535,422 |
| Jude Onyia | Chief Scientific Officer | $7,035,851 |
| Strategic Advisor | — | $6,764,318 |
| Eiry Roberts | Chief Medical Officer | $6,764,318 |
| Matthew C. Abernethy | Chief Financial Officer | $6,595,201 |
| Eric Benevich | Chief Commercial Officer | $6,306,164 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Kevin C. Gorman | Former Chief Executive Officer | $15,750,812 |
| Kevin Gorman | CEO | $15,750,812 |
| Jude Onyia | Chief Scientific Officer | $7,223,216 |
| Matthew C. Abernethy | Chief Financial Officer | $6,057,882 |
| Kyle W. Gano | Chief Executive Officer | $5,990,215 |
| Eiry Roberts | Chief Medical Officer | $5,873,847 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kevin C. Gorman | Former Chief Executive Officer | $11,902,527 |
| Kevin Gorman | CEO | $11,902,527 |
| Eiry Roberts | Chief Medical Officer | $5,735,281 |
| Kyle W. Gano | Chief Executive Officer | $5,421,657 |
| Matthew C. Abernethy | Chief Financial Officer | $4,924,323 |
| Darin M. Lippoldt | Chief Legal Officer | $4,721,196 |
| Jude Onyia | Chief Scientific Officer | $2,461,299 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kevin C. Gorman | Chief Executive Officer | $14,081,412 |
| Kevin Gorman | CEO | $14,081,412 |
| Jude Onyia | Chief Scientific Officer | $7,581,630 |
| Eiry Roberts | Chief Medical Officer | $6,425,596 |
| Matthew C. Abernethy | Chief Financial Officer | $5,906,850 |
| Kyle W. Gano | Chief Business Development and Strategy Officer | $5,811,324 |
| Eric Benevich | Chief Commercial Officer | $5,805,086 |
| Darin M. Lippoldt | Chief Legal Officer | $5,590,161 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Kevin C. Gorman | Chief Executive Officer | $13,880,632 |
| Kevin Gorman | CEO | $13,880,632 |
| Kyle W. Gano | Chief Business Development and Strategy Officer | $7,211,940 |
| Eric Benevich | Chief Commercial Officer | $6,748,960 |
| Matthew C. Abernethy | Chief Financial Officer | $6,281,176 |
| Eiry Roberts | Chief Medical Officer | $5,848,033 |
| Darin M. Lippoldt | Chief Legal Officer | $5,452,362 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Kevin C. Gorman | Chief Executive Officer | $9,450,826 |
| Kevin Gorman | CEO | $9,450,826 |
| Matthew C. Abernethy | Chief Financial Officer | $5,823,120 |
| Eric Benevich | Chief Commercial Officer | $5,793,447 |
| Eiry Roberts | Chief Medical Officer | $4,899,915 |
| Haig P. Bozigian | Chief Development Officer | $4,780,996 |
| Kyle W. Gano | Chief Development and Strategy Officer | $4,725,972 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Kevin Gorman | CEO | $8,632,979 |
| Kevin C. Gorman | Chief Executive Officer | $8,632,979 |
| Eiry Roberts | Chief Medical Officer | $8,300,623 |
| Kyle W. Gano | Chief Development and Strategy Officer | $4,568,241 |
| Eric Benevich | Chief Commercial Officer | $3,672,605 |
| Haig P. Bozigian | Chief Development Officer | $2,993,806 |
| Matthew C. Abernethy | Chief Financial Officer | $2,685,747 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Kevin Gorman | CEO | $7,556,374 |
| Kevin C. Gorman | Chief Executive Officer | $7,556,374 |
| Matthew C. Abernethy | Chief Financial Officer | $3,789,292 |
| Eric Benevich | Chief Commercial Officer | $2,977,602 |
| Haig P. Bozigian | Chief Development Officer | $2,969,434 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Johanna Mercier | Class III Director | Appointed | 2026-05-28 |
| Gary A. Lyons | Class III Director | Appointed | 2026-05-28 |
| Kevin C. Gorman, Ph.D. | Class III Director | Appointed | 2026-05-28 |
| Sanjay Keswani, M.D. | Chief Medical Officer | Appointed | 2025-05-30 |
| Shalini Sharp | Class II Director | Appointed | 2025-05-22 |
| Stephen A. Sherwin, M.D. | Class II Director | Appointed | 2025-05-22 |
| Richard F. Pops | Class II Director | Appointed | 2025-05-22 |
| Kyle W. Gano, Ph.D. | Class II Director | Appointed | 2025-05-22 |
| Sanjay Keswani, M.D. | Chief Medical Officer | Appointed | 2025-04-04 |
| Kyle Gano, Ph.D. | President and Chief Executive Officer | Appointed | 2024-10-11 |
Key facts
CIK
914475
CUSIP
64125C109
13F (30d)
159 filings
157 filers
Visit website
Investor relations